Journal of Medicinal Chemistry · 2010 · 65 citations · 20 references
PharmacyMedicinal ChemistryPharmacologyDrug DesignDrug DiscoveryStructure-activity RelationshipsAntiretroviral TherapyAntiviral AgentsAntiviral PharmacologyLead Compound DesignPotency OptimizationStructure-activity Relationship AnalysisAntiviral Drug DesignAntiviral Structure-activity RelationshipsAntiviral TherapeuticsPhase I Clinical TrialsPhase Iii Clinical TrialsStructure-based Ligand DesignViral Maturation Inhibitors
In our continuing study of triterpene derivatives as potent anti-HIV agents, different C-3 conformationally restricted betulinic acid (BA, 1) derivatives were designed and synthesized in order to explore the conformational space of the C-3 pharmacophore. 3-O-Monomethylsuccinyl-betulinic acid (MSB) analogues were also designed to better understand the contribution of the C-3' dimethyl group of bevirimat (2), the first-in-class HIV maturation inhibitor, which is currently in phase IIb clinical trials. In addition, another triterpene skeleton, moronic acid (MA, 3), was also employed to study the influence of the backbone and the C-3 modification toward the anti-HIV activity of this compound class. This study enabled us to better understand the structure-activity relationships (SAR) of triterpene-derived anti-HIV agents and led to the design and synthesis of compound 12 (EC(50): 0.0006 microM), which displayed slightly better activity than 2 as a HIV-1 maturation inhibitor.
20
Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection
David D. Ho, Avidan U. Neumann, Alan S. Perelson et al. · Nature · 1995 · 4.3K citations
Scott M. Hammer, David Katzenstein, Michael D. Hughes et al. · New England Journal of Medicine · 1996 · 1.1K citations · Full text
HIV-1 Drug Resistance in Newly Infected Individuals
Daniel Boden · JAMA · 1999 · 474 citations